J Shahi1, J R Wright2, Z Gabos3, A Swaminath2. 1. Department of Oncology, McMaster University, Hamilton, ON; 2. Department of Oncology, McMaster University, Hamilton, ON;; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON; 3. Department of Oncology, University of Edmonton, Edmonton, AB.; Cross Cancer Institute at Alberta Health Services, Edmonton, AB.
Abstract
BACKGROUND: The management of small-cell lung cancer (sclc) with radiotherapy (rt) varies, with many treatment regimens having been described in the literature. We created a survey to assess patterns of practice and clinical decision-making in the management of sclc by Canadian radiation oncologists (ros). METHODS: A 35-item survey was sent by e-mail to Canadian ros. The questions investigated the role of rt, the dose and timing of rt, target delineation, and use of prophylactic cranial irradiation (pci) in limited-stage (ls) and extensive-stage (es) sclc. RESULTS: Responses were received from 52 eligible ros. For ls-sclc, staging (98%) and simulation or dosimetric (96%) computed tomography imaging were key determinants of rt suitability. The most common dose and fractionation schedule was 40-45 Gy in 15 once-daily fractions (40%), with elective nodal irradiation performed by 31% of ros. Preferred management of clinical T1/2aN0 sclc favoured primary chemoradiotherapy (64%). For es-sclc, consolidative thoracic rt was frequently offered (88%), with a preferred dose and fractionation schedule of 30 Gy in 10 once-daily fractions (70%). Extrathoracic consolidative rt would not be offered by 23 ros (44%). Prophylactic cranial irradiation was generally offered in ls-sclc (100%) and es-sclc (98%) after response to initial treatment. Performance status, baseline cognition, and pre-pci brain imaging were important patient factors assessed before an offer of pci. CONCLUSIONS: Canadian ros show practice variation in sclc management. Future clinical trials and national treatment guidelines might reduce variability in the treatment of early-stage disease, optimization of dose and targeting in ls-sclc, and definition of suitability for pci or consolidative rt.
BACKGROUND: The management of small-cell lung cancer (sclc) with radiotherapy (rt) varies, with many treatment regimens having been described in the literature. We created a survey to assess patterns of practice and clinical decision-making in the management of sclc by Canadian radiation oncologists (ros). METHODS: A 35-item survey was sent by e-mail to Canadian ros. The questions investigated the role of rt, the dose and timing of rt, target delineation, and use of prophylactic cranial irradiation (pci) in limited-stage (ls) and extensive-stage (es) sclc. RESULTS: Responses were received from 52 eligible ros. For ls-sclc, staging (98%) and simulation or dosimetric (96%) computed tomography imaging were key determinants of rt suitability. The most common dose and fractionation schedule was 40-45 Gy in 15 once-daily fractions (40%), with elective nodal irradiation performed by 31% of ros. Preferred management of clinical T1/2aN0 sclc favoured primary chemoradiotherapy (64%). For es-sclc, consolidative thoracic rt was frequently offered (88%), with a preferred dose and fractionation schedule of 30 Gy in 10 once-daily fractions (70%). Extrathoracic consolidative rt would not be offered by 23 ros (44%). Prophylactic cranial irradiation was generally offered in ls-sclc (100%) and es-sclc (98%) after response to initial treatment. Performance status, baseline cognition, and pre-pci brain imaging were important patient factors assessed before an offer of pci. CONCLUSIONS: Canadian ros show practice variation in sclc management. Future clinical trials and national treatment guidelines might reduce variability in the treatment of early-stage disease, optimization of dose and targeting in ls-sclc, and definition of suitability for pci or consolidative rt.
Authors: Rovel Colaco; Hamid Sheikh; Paul Lorigan; Fiona Blackhall; Paul Hulse; Raffaele Califano; Linda Ashcroft; Paul Taylor; Nicholas Thatcher; Corinne Faivre-Finn Journal: Lung Cancer Date: 2011-10-19 Impact factor: 5.705
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: Stephen G Spiro; Lindsay E James; Robin M Rudd; Colin W Trask; Jeffrey S Tobias; Michael Snee; David Gilligan; Philip A Murray; Mary Carmen Ruiz de Elvira; Katy M O'Donnell; Nicole H Gower; Peter G Harper; Allan K Hackshaw Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Patrick Micke; Andreas Faldum; Tsegay Metz; Kai-Michael Beeh; Fernando Bittinger; Jan-Georg Hengstler; Roland Buhl Journal: Lung Cancer Date: 2002-09 Impact factor: 5.705
Authors: David Schreiber; Justin Rineer; Jeremy Weedon; Dan Vongtama; Angela Wortham; Anne Kim; Peter Han; Kwang Choi; Marvin Rotman Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: Ritsuko Komaki; Rebecca Paulus; David S Ettinger; Gregory M M Videtic; Jeffrey D Bradley; Bonnie S Glisson; Corey J Langer; William T Sause; Walter J Curran; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-05 Impact factor: 7.038
Authors: Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora Journal: Eur Respir J Date: 2017-08-24 Impact factor: 16.671
Authors: Sonam Sharma; Matthew T McMillan; Abigail Doucette; Roger B Cohen; Abigail Berman; William Levin; Charles B Simone; Jacob Shabason Journal: Clin Lung Cancer Date: 2017-12-14 Impact factor: 4.785
Authors: Nadia A Saeed; Lan Jin; Alexander W Sasse; Arya Amini; Vivek Verma; Nataniel H Lester-Coll; Po-Han Chen; Roy H Decker; Henry S Park Journal: J Thorac Dis Date: 2022-02 Impact factor: 2.895
Authors: Sondos Zayed; Hanbo Chen; Emma Ali; George B Rodrigues; Andrew Warner; David A Palma; Alexander V Louie Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-13 Impact factor: 7.038
Authors: Michael Yan; Tzen S Toh; Patricia E Lindsay; Jessica Weiss; Katrina Hueniken; Christy Yeung; Vijithan Sugumar; Dixon Pinto; Tony Tadic; Alexander Sun; Andrea Bezjak; John Cho; Srinivas Raman; Meredith Giuliani; Fabio Ynoe Moraes; Geoffrey Liu; Andrew J Hope; Benjamin H Lok Journal: Clin Transl Radiat Oncol Date: 2021-07-08